OWP Pharmaceuticals, Twinned with a Not-For-Profit (ROW Foundation) Focuses on Affordable Access to Select Neuro/Psych Neuroscience Drugs
NAPERVILLE, Ill., July 12, 2018 /PRNewswire/ -- A potentially important story is unfolding in the pharmaceutical industry, with respect to both a new business model in the US, and a way to relieve human suffering in some parts of the developing world. www.owppharma.com/, www.rowpharma.org
OWP Pharmaceuticals, a new kind of Pharmaceutical Social Enterprise® has pioneered a unique business model to market the highest quality branded generic prescription drugs (initially focused on epilepsy) in the US, and to fund the humanitarian donation of the same medications in the developing world known as "Rest of World."
OWP Pharmaceuticals, an angel investor backed start up in Naperville, IL, a suburb of Chicago, IL, was founded in 2014 to commercialize a family of proven, classic, branded generic drugs for neurologists and psychiatrists throughout the US.
The founders of OWP Pharmaceuticals, Scott Boyer and Bruce Duncan simultaneously established ROW (Rest of World) Foundation, an IRS approved 501 (c) (3) not-for-profit, and endowed ROW with Founder's Stock to enable a durable income stream to advance ROW's mission to give away the same drugs in select developing countries.
OWP Pharmaceuticals came to market in 2017 with Roweepra™ (levetiracetam), Roweepra XR™ (levetiracetam ER) and will be shortly launching Subvenite™ (lamotrigine) in 25 mg, 100 mg, 150 mg, 200 mg and including Starter Kits.
For more information, please visit www.owppharma.com and www.rowpharma.org.
SOURCE OWP Pharmaceuticals, Inc.
Share this article